Hepatitis

The global prevalence of hepatitis C virus (HCV) and hepatitis B virus (HBV) infections - and the accompanying serious health consequences - is a significant problem worldwide. Currently, no vaccine or effective therapies are available for the prevention and treatment of chronic HCV infection. Moreover, end-stage liver disease due to HCV infection has become the leading indication for liver transplantation in the United States. Unfortunately, liver transplantation does not cure HCV. Instead, recurrent HCV infection of the new liver occurs in almost all instances, and some form of liver damage occurs in the vast majority of cases. Despite the existence of vaccines for the prevention of HBV infection, this illness still affects more than 350 million people worldwide, leading to chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Treatment with FDA-approved nucleoside/nucleotide analogues has limited long-term efficacy due to the emergence of resistance, which leads to treatment failure. For these reasons, development of novel and effective antiviral agents against chronic HBV and HCV infection is an urgent unmet medical need.

At Southern Research, the goal of our preclinical anti-hepatitis virus research and development program is the efficient and cost-effective evaluation of the efficacy, toxicity, range, and mechanism of action of our clients' compounds. Utilizing our comprehensive capabilities and expertise, we are committed to working closely with our clients in designing study initiatives that meet their specific research needs.

Our anti-hepatitis B virus and anti-hepatitis C virus capabilities include:

• In Vitro Evaluations
• Antiviral testing
• Custom assay development